Skip to content
To the full analysis

GlaxoSmithKline Pharmaceuticals Stock: Valuation and P/E

GLAXO.NS
$29.43Closing price of 20 Nov 2026MEQIRI Score 74 out of 100

GlaxoSmithKline Pharmaceuticals trades at a P/E of 40.3 (Drug Manufacturers (General) median 17.3, own median of recent years 50.8). It was last lower at the fiscal 2026 year end (37.3).

Daily figure as of 22 Nov 2026

P/E
40.3
P/S
11.1
P/B
24.56
PEG
3.04

P/E on Expected Earnings

The forward P/E of 35.2 divides the price by the earnings per share that 4 analysts expect on average for the next twelve months: $0.84. The twelve months are made up pro rata of the estimates for fiscal 2027 and 2028.

35.2
P/E on fiscal 2027
38.6
on estimated fiscal 2027 earnings ($0.76 per share)
P/E on fiscal 2028
33.5
on estimated fiscal 2028 earnings ($0.88 per share)

Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.

Against Its Own Valuation History

Each fiscal year is shown with its P/E on the year-end date, using the price at the time. From 2017 to 2026 the P/E at fiscal year end ranged from 16.7 (2022) to 228.6 (2020).

P/E
40.3
Median of prior years
50.8
Reading
cheaper than usual

P/E at Each Fiscal Year End

Figures as a table
YearP/E
201769
201850.8
201949.4
2020228.6
202168.2
202216.7
202336.9
202457
202551.1
202637.3

P/E of Industry Peers

StockP/EOwn median
Daiichi Sankyo17.838.4
Orion21.522.2
Zhangzhou Pientzehuang Pharmaceutical.58.949.8
CSPC Pharmaceutical Group10.520.6
Grifols15.230.5
Ono Pharmaceutical15.519.0
GlaxoSmithKline Pharmaceuticals40.350.8
Organon17.85.7
Virbac18.425.0

The eight peers closest in market value, largest first. Trailing twelve-month P/E as of 22 Nov 2026, loss makers have none.

Earnings Yield and Interest Rates

Put the other way round, earnings per share over the last twelve months equal 2.5% of the share price. That is the earnings yield. Ten-year government bonds of the home country (India) yielded 6.9% on average over the last five years, the same rate the fair value uses. So the earnings yield is 4.4 percentage points lower. Unlike interest, earnings are not guaranteed. They fluctuate and can disappear.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy